DGAP-News: CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution

2019. június 18., kedd, 16:10





DGAP-News: CENTOGENE AG / Key word(s): Miscellaneous


CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution


18.06.2019 / 16:10



The issuer is solely responsible for the content of this announcement.



CENTOGENE Accelerates Rare Disease Diagnosis with new Artificial Intelligence Solution



Variant Prioritization Tool Driven by World"s Largest Curated Mutation Database

Cambridge, MA USA & Rostock, Berlin GERMANY, 18 June, 2019. In a whitepaper published today, CENTOGENE revealed the progress it is making with its in-house artificial intelligence (AI) program to accelerate rare disease patient diagnosis. The whitepaper demonstrates how the Company"s latest AI initiative - a variant prioritization tool - has not only accelerated the diagnostics process but also outperforms other tools with regards to sensitivity and specificity for flagging "pathogenic" and "likely pathogenic" variants.



With what is believed to be the world"s largest curated data repository CentoMD(R), which includes epidemiologic, phenotypic and heterogenetic anonymized data of more than 420,000 patients and >7.3 million variants, CENTOGENE is ideally positioned to leverage its "big data" for AI-driven accelerated diagnosis.



"Big data is the key enabler of artificial intelligence since AI systems need enormous data sets to train algorithms. The better and more comprehensive the data, the higher the predictive power and accuracy of results from artificial intelligence," commented Dr. Volkmar Weckesser, CENTOGENE Chief Information Officer. "CENTOGENE finds itself in this enviable position with our data repository CentoMD(R) - our "big data". We have demonstrated that by combining what we believe to be the world"s largest database of genetic information with an AI-based variant prioritization solution, we outperform other tools available and ultimately accelerate the diagnosis of rare disease patients."



Carsten Ullrich, Director of Artificial Intelligence, added: "CENTOGENE"s diagnostic and pharmaceutical solutions rely on the extensive knowledge and insights held in our data repository. Artificial intelligence enables us to find relationships faster, draw more exact conclusions about relationships in the data and discover patterns that cannot be found with traditional methods."



In the diagnosis of rare disease patients, variant prioritization is a vital step in discovering causal variants in order to identify disease-causing mutations. Variant prioritization accelerates and simplifies variant interpretation because the results enable the interpretation of variants of unknown significance. Prioritization scores enable the diagnosis of a patient and, indeed, rare disease diagnosis relies heavily on variant prioritization scores in order to determine which variants are likely to affect the function of genes.



Read the whitepaper: https://www.centogene.com/science/whitepapers/centogenes-variant-prioritization-big-data-and-ai-driving-rare-disease-diagnosis.html.



- end -

 



About CENTOGENE



CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. We are focused on bringing rationality to treatment decisions and accelerating the development of new orphan drugs by using our knowledge of the global rare disease market, including our epidemiological and clinical heterogeneity and our innovative biomarkers.



As one of the largest rare disease companies worldwide, CENTOGENE is dedicated to transforming the science of genetic information into solutions and creating hope for our patients with rare diseases and their families.



 



###




CENTOGENE AG

Ross Bethell

Director, Corporate Communications

ross.bethell@centogene.com
















18.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de





826839  18.06.2019 



fncls.ssp?fn=show_t_gif&application_id=826839&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.